New compounding pharmacy company backed by Bain

A new company financed by Bain Capital intends to stake a position in the sterile compounding market. QuVa Pharma has started by acquiring an FDA 503B registered compounding facility in Sugar Land, TX, from Helix. Terms of the deal were not disclosed. QuVa was founded by Stuart Hinchen, who is CEO, and Peter Jenkins, who is chief development officer. Both executives bring to QuVa Pharma the experience from time at JHP Pharmaceuticals and Mayne Pharma, the company said in a release. "With the support of Bain Capital Private Equity, we will be able to aggressively pursue an expansion strategy," Hinchen said in a statement. The FDA started the registration program for compounding pharmacies last year as part of the Drug Quality and Security Act. Release | More

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.